DexCom (DXCM) Stock Could Be 41% Undervalued As Guidance Rises

DexCom has delivered strong recent gains, yet its longer term record is mixed, which puts the spotlight on whether today's share price is backed by the cash the business can generate. With the stock now trading at US$82.29, the core issue is how that tag lines up with the cash flow profile investors are effectively paying for.

• Over the past 5 years, DexCom shareholders have seen the stock fall 48.2%, which makes the current valuation debate more about cash flow durability than momentum.
• Recent profit growth, product launches and a sizeable share repurchase plan can influence how much cash DexCom is able to return to investors over time and how predictable those streams look.
• What if you looked at DexCom through its earnings instead? See why DexCom's 31.0x P/E tells a different valuation story.

The issue now is whether the cash flows implied by DexCom's current price look well supported by its underlying business economics.

If you want a wider watchlist while you think through DexCom's cash flow story, start with a focused stock screen built around 29 high quality undervalued stocks.

Is DexCom a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) approach here looks at the cash DexCom can return to shareholders over time rather than just its reported earnings. In this model, the firm is working from latest twelve month free cash flow of about $1.39b, with analysts and internal estimates pointing to growing free cash flow in the coming decade as the business scales. That growth path matters more than a single year, since the valuation leans heavily on DexCom continuing to turn a meaningful share of its revenue into excess cash.

The DCF output suggests these projected cash flows support an intrinsic worth that is substantially above the current share price of $82.29. The raised full year 2026 guidance and new $1.0b buyback plan help explain why projected cash returns appear robust enough for the model to land above where the market is pricing DexCom today. You can see the full DCF assumptions and how that gap is calculated in detail here. Find out what DexCom could be worth using our Discounted Cash Flow (DCF) estimate.

The DexCom Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for DexCom pick up where the DCF puzzle leaves off. They spell out which paths for DexCom's growth, margins and earnings would need to hold for the share price to look meaningfully higher or lower than today, and show in plain terms the future story that sits behind any single valuation number so you can watch over time whether that story is actually playing out. These are available on Simply Wall St's Community page and turn a static output into a set of concrete assumptions you can monitor.

The DexCom community splits between those who think the cash and margin profile leaves more on the table and those who see expectations as already demanding.

Bull case: 17% undervalued

"Dexcom is raising the midpoint of fiscal year 2026 Revenue guidance and increasing fiscal year 2026 guidance for Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin to the following levels…"

Discover why this Narrative puts DexCom at 17% undervalued.

Bear case: roughly fairly valued

"Although broader commercial coverage for type 2 diabetes patients not using insulin, including more than 6 million covered lives across large PBMs and an expected expansion to over 7 million with Prime Therapeutics, supports a larger addressable base, future revenue growth still depends on converting the roughly two thirds of covered patients who are not yet using CGM…"

Explore why this Narrative puts DexCom at roughly fairly valued.

One more piece of the DexCom puzzle worth checking

Cash flows and guidance tell only part of DexCom's story, because the people setting priorities and how they are rewarded can shape every decision that follows. See who runs DexCom and how they are paid.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com